Experienced high-tech executive with expertise in startups, IPOs, M&A, and leading engineering teams. Previous executive roles at Radview (RDVW) - from inception to a Nasdaq IPO, and Radware (Nasdaq: RDWR) - tripling annual revenues to $250M and reaching $1.2B valuation. Skilled in leadership, technology, and business growth. Studies Mathematics, Computer Sciences, and Neuroscience. Based in New York City.

Doron is the Co-Founder and former CTO of Foamix Pharma (Nasdaq: FOMX), with extensive leadership as VP R&D at Lipocure, where he advanced the first FDA-approved liposome anti-cancer nano-drug (generic Doxil), and at Ayana Pharma. He also served as Managing Partner at MII Fund & Labs and holds a PhD in Pharmaceutical Sciences from the Hebrew University.

Robert Rioux has 25 years of experience in developing and commercializing medical devices across Oncology, Blood Processing, Surgical, Orthopedic, Gynecology and Wound Care. In the past three years, Bob led efforts securing 2 FDA 510(k)s, 2 CE Marks, and 2 breakthrough designations. He holds 134 issued US patents, reflecting his innovation and leadership in the field.